Skip to main content
Join CMKC members for a complimentary virtual event on December 10, 11am ET: CM MythBusters: https://bit.ly/3YXJynA. This is a fantastic opportunity to connect, collaborate, and debunk common myths about continuous manufacturing!
18.119.113.79

Tags: Artemisinin

All Categories (1-4 of 4)

  1. Continuous synthesis of artemisinin-derived medicines

    24 Apr 2024 | Contributor(s):: Gilmore, Kerry, Kopetzki, Daniel, Lee, Ju Weon, Horváth, Zoltán, McQuade, D. Tyler, Seidel-Morgenstern, Andreas, Seeberger, Peter H.

    Described is a continuous, divergent synthesis system which is coupled to continuous purification and is capable of producing four anti-malarial APIs. The system is comprised of three linked reaction modules for photooxidation/cyclization, reduction, and derivatization. A fourth module couples...

  2. Continuous-flow synthesis of the anti-malaria drug artemisinin

    24 Apr 2024 | Contributor(s):: Lévesque, François, Seeberger, Peter H

    Malaria is a serious global health issue. Artemisinin combination treatments are the first-line drugs, but supplies are limited because artemisinin is obtained solely by extraction from Artemisia annua. A continuous-flow process that converts dihydroartemisinic acid into artemisinin (see scheme)...

  3. Technoeconomic optimisation and comparative environmental impact evaluation of continuous crystallisation and antisolvent selection for artemisinin recovery

    09 Jun 2023 | Contributor(s):: Jolliffe, HG, Gerogiorgis, DI

    Systematic nonlinear optimisation is a valuable tool towards evaluating the performance of conceptual Continuous Pharmaceutical Manufacturing (CPM) flowsheets. This study considers total cost minimisation of multiple plausible design choices and eight candidate antisolvents for the continuous...

  4. Plantwide design and economic evaluation of two Continuous Pharmaceutical Manufacturing (CPM) cases: Ibuprofen and artemisinin

    09 Jun 2023 | Contributor(s):: Jolliffe, HG, Gerogiorgis, DI

    Increasing Research Article and Development (R&D) costs, growing competition from generic manufacturers and dwindling market introduction rates for novel drug products bolster the efforts of pharmaceutical firms to secure competitiveness by investigating Continuous Pharmaceutical Manufacturing...